Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765308943> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2765308943 endingPage "A436" @default.
- W2765308943 startingPage "A436" @default.
- W2765308943 abstract "To evaluate the cost-effectiveness of ponatinib compared to bosutinib, allogeneic stem cell transplantation (allo-SCT) and hydroxycarbamide in the treatment of adult patients with accelerated or blast phase - Chronic Myeloid Leukemia (AP/ΒP-CML) whose disease is resistant/ intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation in the Greek healthcare setting. A markov model was locally adapted from a third-party payer perspective over a 50-year time horizon. Efficacy, safety and utility data were extracted from relevant clinical trials and the literature. Resource consumption data were obtained from local experts and were combined with unit costs (in €2017) obtained from official sources. Primary outcomes were patient quality-adjusted life years (QALYs), total costs and incremental cost-effectiveness ratios (ICERs) per QALY gained. All the future outcomes were discounted at 3.5% per annum. A probabilistic sensitivity analysis (PSA) was conducted. Total life time cost per patient in BP-CML was estimated at €29,895, €16,038, €42,893, and €8,609 for ponatinib, bosutinib, allo-SCT and hydroxycarbamide, respectively. In terms of health outcomes, ponatinib was associated with 0.96, 0.48 and 1.05 increment in QALYs compared with bosutinib, allo-SCT, and hydroxycarbamide respectively, resulting in ICERs of €14,481 and €20,288 per QALY gained versus bosutinib and hydroxycarbamide. Similar results were found in AP-CML with ICERs reaching at €679 and €13,878 per QALY gained, respectively. Moreover, ponatinib was a dominant alternative over allo-SCT in both AP/BP-CML. PSA revealed that the probability of ponatinib being a cost-effective option at the predetermined threshold of €51,000 per QALY gained was higher than 95% versus all available comparators in both AP/BP- CML. The results indicate that, ponatinib seems to be a cost–effective option compared to other alternative therapies in the treatment of AP/BP-CML patients in Greece." @default.
- W2765308943 created "2017-11-10" @default.
- W2765308943 creator A5014525409 @default.
- W2765308943 creator A5025529105 @default.
- W2765308943 creator A5052953879 @default.
- W2765308943 creator A5072838496 @default.
- W2765308943 creator A5073478319 @default.
- W2765308943 date "2017-10-01" @default.
- W2765308943 modified "2023-09-26" @default.
- W2765308943 title "Cost-Effectiveness of Ponatinib in The Treatment of Patients With Accelerated or Blast Phase - Chronic Myeloid Leukemia in Greece" @default.
- W2765308943 doi "https://doi.org/10.1016/j.jval.2017.08.219" @default.
- W2765308943 hasPublicationYear "2017" @default.
- W2765308943 type Work @default.
- W2765308943 sameAs 2765308943 @default.
- W2765308943 citedByCount "1" @default.
- W2765308943 countsByYear W27653089432023 @default.
- W2765308943 crossrefType "journal-article" @default.
- W2765308943 hasAuthorship W2765308943A5014525409 @default.
- W2765308943 hasAuthorship W2765308943A5025529105 @default.
- W2765308943 hasAuthorship W2765308943A5052953879 @default.
- W2765308943 hasAuthorship W2765308943A5072838496 @default.
- W2765308943 hasAuthorship W2765308943A5073478319 @default.
- W2765308943 hasBestOaLocation W27653089431 @default.
- W2765308943 hasConcept C112930515 @default.
- W2765308943 hasConcept C126322002 @default.
- W2765308943 hasConcept C143998085 @default.
- W2765308943 hasConcept C2777413986 @default.
- W2765308943 hasConcept C2777583451 @default.
- W2765308943 hasConcept C2778208673 @default.
- W2765308943 hasConcept C2778729363 @default.
- W2765308943 hasConcept C2779134260 @default.
- W2765308943 hasConcept C2779316324 @default.
- W2765308943 hasConcept C2779536868 @default.
- W2765308943 hasConcept C2780381907 @default.
- W2765308943 hasConcept C2911091166 @default.
- W2765308943 hasConcept C3019080777 @default.
- W2765308943 hasConcept C64332521 @default.
- W2765308943 hasConcept C71924100 @default.
- W2765308943 hasConceptScore W2765308943C112930515 @default.
- W2765308943 hasConceptScore W2765308943C126322002 @default.
- W2765308943 hasConceptScore W2765308943C143998085 @default.
- W2765308943 hasConceptScore W2765308943C2777413986 @default.
- W2765308943 hasConceptScore W2765308943C2777583451 @default.
- W2765308943 hasConceptScore W2765308943C2778208673 @default.
- W2765308943 hasConceptScore W2765308943C2778729363 @default.
- W2765308943 hasConceptScore W2765308943C2779134260 @default.
- W2765308943 hasConceptScore W2765308943C2779316324 @default.
- W2765308943 hasConceptScore W2765308943C2779536868 @default.
- W2765308943 hasConceptScore W2765308943C2780381907 @default.
- W2765308943 hasConceptScore W2765308943C2911091166 @default.
- W2765308943 hasConceptScore W2765308943C3019080777 @default.
- W2765308943 hasConceptScore W2765308943C64332521 @default.
- W2765308943 hasConceptScore W2765308943C71924100 @default.
- W2765308943 hasIssue "9" @default.
- W2765308943 hasLocation W27653089431 @default.
- W2765308943 hasOpenAccess W2765308943 @default.
- W2765308943 hasPrimaryLocation W27653089431 @default.
- W2765308943 hasRelatedWork W1554937972 @default.
- W2765308943 hasRelatedWork W1976491322 @default.
- W2765308943 hasRelatedWork W2114348747 @default.
- W2765308943 hasRelatedWork W2155107050 @default.
- W2765308943 hasRelatedWork W2209596544 @default.
- W2765308943 hasRelatedWork W2401908067 @default.
- W2765308943 hasRelatedWork W2766481094 @default.
- W2765308943 hasRelatedWork W2952141298 @default.
- W2765308943 hasRelatedWork W388027184 @default.
- W2765308943 hasRelatedWork W4363673819 @default.
- W2765308943 hasVolume "20" @default.
- W2765308943 isParatext "false" @default.
- W2765308943 isRetracted "false" @default.
- W2765308943 magId "2765308943" @default.
- W2765308943 workType "article" @default.